PMID- 20715159
OWN - NLM
STAT- MEDLINE
DCOM- 20110215
LR  - 20220311
IS  - 0008-543X (Print)
IS  - 1097-0142 (Electronic)
IS  - 0008-543X (Linking)
VI  - 116
IP  - 23
DP  - 2010 Dec 1
TI  - The prevalence and assessment of ErbB2-positive breast cancer in Asia: a 
      literature survey.
PG  - 5348-57
LID - 10.1002/cncr.25476 [doi]
AB  - Overexpression of the epidermal growth factor receptor-related gene ErbB2 occurs 
      in 18% to 25% of patients with breast cancer in Western countries and is 
      associated with a poor prognosis. The prevalence of ErbB2-positive tumors in Asia 
      is unclear, partly because data are limited. The objective of this review was to 
      summarize the reported prevalence of ErbB2-positive tumors from a large sample of 
      Asian patients and to examine ErbB2 assessment methods in Asia. From searches of 
      MEDLINE, local language journals, and local and international conference 
      proceedings as well as locoregional breast cancer experts' recommendations, the 
      authors selected up to 5 studies each from India, Korea, Malaysia, the 
      Philippines, Singapore, Taiwan, and Thailand that reported ErbB2 results based on 
      assessment with immunohistochemistry (IHC) and/or fluorescence in situ 
      hybridization (FISH). The reported prevalence of ErbB2-positive tumors in 22 
      studies on 24,671 patients, of whom 14,398 patients were assessed for ErbB2 
      status, varied widely (range, 6%-65%) as did the assessment methods used. Most 
      studies (n=21) used IHC to assess ErbB2 status, but definitions for positivity 
      varied. When robust assessment methods were used, the median prevalence was 19% 
      based on strong IHC staining (IHC3+; n=9812 patients) and 25% based on FISH 
      (n=681 patients). Data on the prevalence of ErbB2-positive breast cancer in Asia 
      are limited. The current survey indicated that the prevalence in Asia may be 
      similar to that in Western countries; thus, up to 1 in 4 Asian patients with 
      breast cancer potentially could benefit from ErbB2-targeted treatment. A 
      standard, reliable ErbB2 assessment method available to patients across Asia is 
      urgently required.
CI  - Copyright (c) 2010 American Cancer Society.
FAU - Tan, Yew Oo
AU  - Tan YO
AD  - Medical Oncology Center, Gleneagles Medical Center, Singapore.
FAU - Han, Sehwan
AU  - Han S
FAU - Lu, Yen-Shen
AU  - Lu YS
FAU - Yip, Cheng-Har
AU  - Yip CH
FAU - Sunpaweravong, Patrapim
AU  - Sunpaweravong P
FAU - Jeong, Joon
AU  - Jeong J
FAU - Caguioa, Priscilla B
AU  - Caguioa PB
FAU - Aggarwal, Shyam
AU  - Aggarwal S
FAU - Yeoh, Ee Min
AU  - Yeoh EM
FAU - Moon, Hanlim
AU  - Moon H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20100816
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Asia
MH  - Breast Neoplasms/*epidemiology/*genetics
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Prevalence
MH  - Receptor, ErbB-2/*genetics
PMC - PMC3038357
EDAT- 2010/08/18 06:00
MHDA- 2011/02/16 06:00
CRDT- 2010/08/18 06:00
PHST- 2010/03/10 00:00 [received]
PHST- 2010/05/10 00:00 [revised]
PHST- 2010/05/13 00:00 [accepted]
PHST- 2010/08/18 06:00 [entrez]
PHST- 2010/08/18 06:00 [pubmed]
PHST- 2011/02/16 06:00 [medline]
AID - 10.1002/cncr.25476 [doi]
PST - ppublish
SO  - Cancer. 2010 Dec 1;116(23):5348-57. doi: 10.1002/cncr.25476. Epub 2010 Aug 16.